Pharmacogenetics of migraine: Genetic variants and their potential role in migraine therapy

Pharmacogenomics

Volumn 8, Issue 6, 2007, Pages 609-622

  Fernandez, F ^a   Colson, N J ^a   Griffiths, L R ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Biomarkers; Migraine; SNP; Therapy

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALMOTRIPTAN; AMITRIPTYLINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ELETRIPTAN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN A RECEPTOR; FLUNARIZINE; FOLIC ACID; FROVATRIPTAN; INSULIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; LYMPHOTOXIN; NARATRIPTAN; NIFEDIPINE; NIMODIPINE; PLACEBO; RIZATRIPTAN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VERAPAMIL; ZOLMITRIPTAN;

CLINICAL FEATURE; CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG TARGETING; FAMILIAL HEMIPLEGIC MIGRAINE; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; INDIVIDUALIZATION; MENTAL DISEASE; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PHARMACOGENETICS; REVIEW; SEDATION; SEX RATIO; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; HUMANS; MIGRAINE DISORDERS; MUTATION; PHARMACOGENETICS; VARIATION (GENETICS);

EID: 34250620103     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.6.609     Document Type: Review

References (96)

1. HCCIHS. Headache Classification Committee for the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain 2nd edition. Cephalgia 24(Suppl. 1), 1-60 (2004).
2. Silberstein SD: Preventive treatment of migraine. Trends Pharmacol. Sci. 27(8), 410-415 (2006).
3. Montagna P, Pierangeli G, Cevoli S, Mochi M, Cortelli P: Pharmacogenetics of headache treatment. Neurol. Sci. 26(Suppl. 2), s143-s147 (2005).
4. Buzzi MG, Moskowitz MA: The pathophysiology of migraine: year 2005. J. Headache Pain 6(3), 105-111 (2005).
5. Ambrosini A, Schoenen J: Electrophysiological response patterns of primary sensory cortices in migraine. J. Headache Pain 7(6), 377-388 (2006).
6. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA: Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat. Med. 8(2), 136-142 (2002).
7. Goadsby PJ: Migraine pathophysiology. Headache 45(Suppl. 1), S14-S24 (2005).
8. May A: A review of diagnostic and functional imaging in headache. J. Headache Pain 7(4), 174-184 (2006).
9. Wieser T, Mueller C, Evers S, Zierz S, Deufel T: Absence of known familial hemiplegic migraine (FHM) mutations in the CACNA1A gene in patients with common migraine: implications for genetic testing. Clin. Chem. Lab. Med. 41(3), 272-275 (2003).
10. Rehavi M, Carmi R, Weizman A: Tricyclic antidepressants and calcium channel blockers: interactions at the (-)-desmethoxyverapamil binding site and the serotonin transporter. Eur. J. Pharmacol. 155(1-2), 1-9 (1988).
11. Pietrobon D: Familial hemiplegic migraine. Neurotherapeutics 4(2), 274-284 (2007).
12. Silberstein SD, Lipton RB: Chronic daily headache. Curr. Opin. Neurol. 13(3), 277-283 (2000).
13. Goadsby PJ, Edvinsson L, Ekman R: Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann. Neurol. 23(2), 193-196 (1988).
14. Sarchielli P, Alberti A, Codini M, Floridi A, Gallai V: Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 20(10), 907-918 (2000).
15. Goadsby PJ, Edvinsson L: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. 33(1), 48-56 (1993).
16. Ferrari MD, Loder E, McCarroll KA, Lines CR: Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials. Cephalalgia 21(2), 129-136 (2001).
17. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ: Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358(9294), 1668-1675 (2001).
18. Dodick DW, Sandrini G, Williams P: Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs 21(1), 73-82 (2007).
19. Maassen VanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR: Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 98(1), 25-30 (1998).
20. Maassen VanDenBrink A, Vergouwe MN, Ophoff RA, Saxena PR, Ferrari MD, Frants RR: 5-HT1B receptor polymorphism and clinical response to sumatriptan. Headache 38(4), 288-291 (1998).
21. Kusumi M, Araki H, Ijiri T et al.: Serotonin 2C receptor gene Cys23Ser polymorphism: a candidate genetic risk factor of migraine with aura in Japanese population. Acta Neurol. Scand. 109(6), 407-409 (2004).
22. Johnson MP, Lea RA, Curtain RP, MacMillan JC, Griffiths LR: An investigation of the 5-HT2C receptor gene as a migraine candidate gene. Am. J. Med. Genet. 117B(1), 86-89 (2003).
23. Johnson MP, Griffiths LR: A genetic analysis of serotonergic biosynthetic and metabolic enzymes in migraine using a DNA pooling approach. J. Hum. Genet. 50(12), 607-610 (2005).
24. Marziniak M, Mossner R, Benninghoff J, Syagailo YV, Lesch KP, Sommer C: Association analysis of the functional monoamine oxidase A gene promotor polymorphism in migraine. J. Neural Transm. 111(5), 603-609 (2004).
25. Erdal N, Herken H, Yilmaz M, Erdal E, Bayazit YA: The A218C polymorphism of tryptophan hydroxylase gene and migraine. J. Clin. Neurosci. 14(3), 249-251 (2007).
26. Ogilvie AD, Russell MB, Dhall P et al.: Altered allelic distributions of the serotonin transporter gene in migraine without aura and migraine with aura. Cephalalgia 18(1), 23-26 (1998).
27. Yilmaz M, Erdal ME, Herken H, Cataloluk O, Barlas O, Bayazit YA: Significance of serotonin transporter gene polymorphism in migraine. J. Neurol. Sci. 186(1-2), 27-30 (2001).
28. Juhasz G, Zsombok T, Laszik A et al.: Association analysis of 5-HTTLPR variants, 5-HT2a receptor gene 102T/C polymorphism and migraine. J. Neurogenet. 17(2-3), 231-240 (2003).
29. Marziniak M, Mossner R, Schmitt A, Lesch KP, Sommer C: A functional serotonin transporter gene polymorphism is associated with migraine with aura. Neurology 64(1), 157-159 (2005).
30. Molgat CV, Patten SB: Comorbidity of major depression and migraine - a Canadian population-based study. Can. J. Psychiatry 50(13), 832-837 (2005).
31. Peroutka SJ, Wilhoit T, Jones K: Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology 49(1), 201-206 (1997).
32. Ramadan NM: Current trends in migraine prophylaxis. Headache 47(Suppl. 1), S52-S57 (2007).
33. Modi S, Lowder DM: Medications for migraine prophylaxis. Am. Fam. Physician 73(1), 72-78 (2006).
34. Spoont MR: Modulatory role of serotonin in neural information processing: implications for human psychopathology. Psychol. Bull. 112(2), 330-350 (1992).
35. Peroutka SJ: Migraine: a chronic sympathetic nervous system disorder. Headache 44(1), 53-64 (2004).
36. Fanciullacci M, Alessandri M, Del Rosso A: Dopamine involvement in the migraine attack. Funct. Neurol. 15(Suppl. 3), 171-81 (2000).
37. Bes A, Dupui P, Guell A, Bessoles G, Geraud G: Pharmacological exploration of dopamine hypersensitivity in migraine patients. Int. J. Clin. Pharmacol. Res. 6(3), 189-192 (1986).
38. Coppola M, Yealy DM, Leibold RA: Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann. Emerg. Med. 26(5), 541-546 (1995).
39. Joubert J: Migraine - diagnosis and treatment. Aust. Fam. Physician 34(8), 627-632 (2005).
40. Honkaniemi J, Liimatainen S, Rainesalo S, Sulavuori S: Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. Headache 46(5), 781-787 (2006).
41. Lea RA, Dohy A, Jordan K, Quinlan S, Brimage PJ, Griffiths LR: Evidence for allelic association of the dopamine β-hydroxylase gene (DBH) with susceptibility to typical migraine. Neurogenetics 3(1), 35-40 (2000).
42. Fernandez F, Lea RA, Colson NJ, Bellis C, Quinlan S, Griffiths LR: Association between a 19 bp deletion polymorphism at the dopamine β-hydroxylase (DBH) locus and migraine with aura. J. Neurol. Sci. 251(1-2), 118-123 (2006).
43. Maude S, Curtin J, Breen G et al.: The - 141C Ins/Del polymorphism of the dopamine D2 receptor gene is not associated with either migraine or Parkinson's disease. Psychiatr. Genet. 11(1), 49-52 (2001).
44. Rebaudengo N, Rainero I, Parziale A et al.: Lack of interaction between a polymorphism in the dopamine D2 receptor gene and the clinical features of migraine. Cephalalgia 24(6), 503-507 (2004).
45. Strous RD, Bark N, Woerner M, Lachman HM: Lack of association of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia. Biol. Psychiatry 41(4), 493-495 (1997).
46. Erdal ME, Herken H, Yilmaz M, Bayazit YA: Association of the T102C polymorphism of 5-HT2A receptor gene with aura in migraine. J. Neurol. Sci. 188(1-2), 99-101 (2001).
47. Mossner R, Freitag CM, Marziniak M, Moser D, Sommer C, Meyer J: The functional Val158Met variant of the COMT gene is not associated with migraine with or without aura. J. Headache Pain 7(3), 165-166 (2006).
48. Hagen K, Pettersen E, Stovner LJ, Skorpen F, Zwart JA: The association between headache and Val158Met polymorphism in the catechol-O-methyltransferase gene: the HUNT Study. J. Headache Pain 7(2), 70-74 (2006).
49. Moskowitz MA, Macfarlane R: Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc. Brain Metab. Rev. 5(3), 159-177 (1993).
50. Harker LA, Harlan JM, Ross R: Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ. Res. 53(6), 731-739 (1983).
51. Cutrer FM, Sorensen AG, Weisskoff RM et al.: Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann. Neurol. 43(1), 25-31 (1998).
52. Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Nakashima K: The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am. J. Med. Genet. 96(6), 762-764 (2000).
53. Kara I, Sazci A, Ergul E, Kaya G, Kilic G: Association of the C677T and A1298C polymorphisms in the 5,10 methylenetetrahydrofolate reductase gene in patients with migraine risk. Brain Res. Mol. Brain Res. 111(1-2), 84-90 (2003).
54. Lea RA, Ovcaric M, Sundholm J, Solyom L, Macmillan J, Griffiths LR: Genetic variants of angiotensin converting enzyme and methylenetetrahydrofolate reductase may act in combination to increase migraine susceptibility. Brain Res. Mol. Brain Res. 136(1-2), 112-117 (2005).
55. Oterino A, Valle N, Bravo Y et al.: MTHFR T677 homozygosis influences the presence of aura in migraineurs. Cephalalgia 24(6), 491-494 (2004).
56. Kaunisto MA, Kallela M, Hamalainen E et al.: Testing of variants of the MTHFR and ESR1 genes in 1798 Finnish individuals fails to confirm the association with migraine with aura. Cephalalgia 26(12), 1462-1472 (2006).
57. Scher AI, Terwindt GM, Verschuren WM et al.: Migraine and MTHFR C677T genotype in a population-based sample. Ann. Neurol. 59(2), 372-375 (2006).
58. Ikeda U, Yamamoto K, Maeda Y, Shimpo M, Kanbe T, Shimada K: Endothelin-1 inhibits nitric oxide synthesis in vascular smooth muscle cells. Hypertension 29(1 Pt 1), 65-69 (1997).
59. Tzourio C, El Amrani M, Poirier O, Nicaud V, Bousser MG, Alperovitch A: Association between migraine and endothelin type A receptor (ETA-231 A/G) gene polymorphism. Neurology 56(10), 1273-1277 (2001).
60. Lisi V, Garbo G, Battistella P et al.: Endothelin receptor A -231 G>A polymorphism: no linkage to primary pediatric headache. Headache 46(3), 486-491 (2006).
61. Moncada S, Higgs EA: Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur. J. Clin. Invest. 21(4), 361-374 (1991).
62. Bethea CL, Lu NZ, Gundlah C, Streicher JM: Diverse actions of ovarian steroids in the serotonin neural system. Front. Neuroendocrinol. 23(1), 41-100 (2002).
63. Colson NJ, Lea RA, Quinlan S, MacMillan J, Griffiths LR: The estrogen receptor 1 G594A polymorphism is associated with migraine susceptibility to typical migraine. Neurogenetics 5(2), 129-133 (2004).
64. Oterino A, Pascual J, Ruizde Alegria C et al.: Association of migraine and ESR1 G325C polymorphism. Neuroreport 17(1), 61-64 (2006).
65. Colson NJ, Lea RA, Quinlan S, Griffiths LR: No role for estrogen receptor 1 gene intron 1 Pvu II and exon 4 C325G polymorphisms in migraine susceptibility. BMC Med. Genet. 7, 12 (2006).
66. Colson NJ, Lea RA, Quinlan S, MacMillan J, Griffiths LR: Investigation of hormone receptor genes in migraine. Neurogenetics 6(1), 17-23 (2005).
67. Pradalier A, Launay JM: Immunological aspects of migraine. Biomed. Pharmacother. 50(2), 64-70 (1996).
68. Moore TL, Ryan RE Jr, Pohl DA, Roodman ST, Ryan RE Sr: Immunoglobulin, complement, and immune complex levels during a migraine attack. Headache 20(1), 9-12 (1980).
69. Munno I, Centonze V, Marinaro M et al.: Cytokines and migraine: increase of IL-5 and IL-4 plasma levels. Headache 38(6), 465-467 (1998).
70. Rainero I, Pinessi L, Salani G et al.: A polymorphism in the interleukin-1α gene influences the clinical features of migraine. Headache 42(5), 337-340 (2002).
71. Rainero I, Salani G, Valfre W et al.: Absence of linkage between the interleukin-6 gene (-174G/C) polymorphism and migraine. Neurosci. Lett. 343(3), 155-158 (2003).
72. Fassbender K, Rossol S, Kammer T et al.: Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J. Neurol. Sci. 122(2), 135-139 (1994).
73. Rainero I, Grimaldi LM, Salani G et al.: Association between the tumor necrosis factor-α-308 G/A gene polymorphism and migraine. Neurology 62(1), 141-143 (2004).
74. Mazaheri S, Hajilooi M, Rafiei A: The G-308A promoter variant of the tumor necrosis factor-α gene is associated with migraine without aura. J. Neurol. 253(12), 1589-1593 (2006).
75. Trabace S, Brioli G, Lulli P et al.: Tumor necrosis factor gene polymorphism in migraine. Headache 42(5), 341-345 (2002).
76. Castro-Gago M, Rodriguez-Nunez A, Novo I, Paz M, Rodriguez-Segade S: Migraine in childhood: lipid metabolism and its implications. An. Esp. Pediatr. 30(6), 443-446 (1989).
77. Mochi M, Cevoli S, Cortelli P et al.: Investigation of an LDLR gene polymorphism (19p13.2) in susceptibility to migraine without aura. J. Neurol. Sci. 213(1-2), 7-10 (2003).
78. McCarthy LC, Hosford DA, Riley JH et al.: Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. Genomics 78(3), 135-149 (2001).
79. Lindner V, Booth C, Prudovsky I, Small D, Maciag T, Liaw L: Members of the Jagged/Notch gene families are expressed in injured arteries and regulate cell phenotype via alterations in cell matrix and cell-cell interaction. Am. J. Pathol. 159(3), 875-883 (2001).
80. Schwaag S, Evers S, Schirmacher A, Stogbauer F, Ringelstein EB, Kuhlenbaumer G: Genetic variants of the NOTCH3 gene in migraine - a mutation analysis and association study. Cephalalgia 26(2), 158-161 (2006).
81. Borroni B, Brambilla C, Liberini P et al.: Investigating the association between Notch3 polymorphism and migraine. Headache 46(2), 317-321 (2006).
82. Khaja R, Zhang J, MacDonald JR et al.: Genome assembly comparison identifies structural variants in the human genome. Nat. Genet. 38(12), 1413-1418 (2006).
83. Lander ES, Linton LM, Birren B et al.: Initial sequencing and analysis of the human genome. Nature 409(6822), 860-921 (2001).
84. Botstein D, Risch N: Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat.Genet. 33(Suppl.) 228-237 (2003).
85. Wjst M: Target SNP selection in complex disease association studies. BMC Bioinformatics 5, 92 (2004).
86. Diener HC: Which triptan is best? Rating of triptans in migraine treatment. Pharm. Unserer Zett 31(5), 462-469 (2002).
87. Atar I, Gulmez O, Atar A et al.: The effects of prior β-blocker therapy on serum C-reactive protein levels after percutaneous coronary intervention. Clin. Cardiol. 28(5), 243-246(2005).
88. Korkmaz ME, Atar I, Tayfun E et al.: Effects of a β-blocker and spironolactone on plasma homocysteine levels. Int. J. Cardiol. 91(2-3), 259-260 (2003).
89. de Tommaso M, Difruscolo O, Sardaro M et al.: Influence of MTHFR genotype on contingent negative variation and MRI abnormalities in migraine. Headache 47(2), 253-265 (2007).
90. Geppetti P, Capone JG, Trevisani M, Nicoletti P, Zagli G, Tola MR: CGRP and migraine: neurogenic inflammation revisited. J. Headache Pain 6(2), 61-70 (2005).
91. Durham PL: Calcitonin gene-related peptide (CGRP) and migraine. Headache 46(Suppl.1), S3-S8 (2006).
92. Moreno MJ, Abounader R, Hebert E, Doods H, Hamel E: Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment. Neuropharmacology 42(4), 568-576 (2002).
93. Olesen J, Diener HC, Husstedt IW et al.: Calcitonin gene-related peptide receptor antagonist BIBN 4096BS for the acute treatment of migraine. N.Engl. J.Med. 350(11), 1104-1110 (2004).
94. Burnet PW, Harrison PJ, Goodwin GM et al.: Allelic variation in the serotonin 5-HT2C receptor gene and migraine. Neuroreport 8(12), 2651-2653 (1997).
95. Lea RA, Dohy A, Jordan K, Quinlan S, Brimage PJ, Griffiths LR: Evidence for allelic association of the dopamine β-hydroxylase gene (DBH) with susceptibility to typical migraine. Neurogenetics 3(1), 35-40 (2000).
96. Emin Erdal M, Herken H, Yilmaz M, Bayazit YA: Significance of the catechol-O-methyltransferase gene polymorphism in migraine. Brain Res. Mol. Brain Res. 94(1-2), 193-196 (2001).